Pantalone, DO, ECNU Incretin-based drug therapies such as glucagon-like peptide-1 (GLP-1) receptor agonists and dual glucose-dependent insulinotropic peptide and GLP-1 receptor agonists are rapidly becoming first-line options for treating type 2 diabetes
Lancet 2009;374:1606-16.ArticlePubMed 20
While the first two are outside of our control, there are things we can do about the latter
From an anxiety perspective, stopping the medication removes both any potential anxiety-causing effects and any potential anxiety-protective effects
If weight drops below goal, consider further dose reduction
Research peptides arrive as powder requiring reconstitution with bacteriostatic water, calculation of proper dosing, and injection using standard insulin syringes